Fmr LLC Acquires 20,930 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Fmr LLC grew its stake in Humacyte, Inc. (NASDAQ:HUMA) by 28.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 94,387 shares of the company’s stock after purchasing an additional 20,930 shares during the period. Fmr LLC’s holdings in Humacyte were worth $513,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of HUMA. Renaissance Technologies LLC grew its position in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the period. Thrivent Financial for Lutherans acquired a new stake in shares of Humacyte in the 3rd quarter valued at $712,000. Millennium Management LLC grew its holdings in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after purchasing an additional 1,334,641 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after purchasing an additional 97,931 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in Humacyte by 1,018.4% during the 2nd quarter. AQR Capital Management LLC now owns 256,342 shares of the company’s stock valued at $1,230,000 after purchasing an additional 233,422 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Stock Down 6.8 %

NASDAQ HUMA opened at $3.54 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. Humacyte, Inc. has a 52 week low of $2.48 and a 52 week high of $9.97. The stock has a market capitalization of $445.54 million, a P/E ratio of -2.64 and a beta of 1.38. The stock has a fifty day moving average of $4.89 and a 200-day moving average of $5.88.

Insider Buying and Selling

In other news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now owns 1,730,884 shares of the company’s stock, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,500,000 shares of company stock worth $6,606,799 over the last three months. 11.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Thursday, November 21st. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $13.00.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.